Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CTKB 
Cytek Biosciences Inc (CTKB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: CTKB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.12
1 Year Target Price $5.12
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.87% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 489.81M USD | Price to earnings Ratio - | 1Y Target Price 5.12 |
Price to earnings Ratio - | 1Y Target Price 5.12 | ||
Volume (30-day avg) 6 | Beta 1.32 | 52 Weeks Range 2.37 - 7.63 | Updated Date 10/13/2025 |
52 Weeks Range 2.37 - 7.63 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.27% | Operating Margin (TTM) -23.3% |
Management Effectiveness
Return on Assets (TTM) -3.77% | Return on Equity (TTM) -1.67% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 226023789 | Price to Sales(TTM) 2.5 |
Enterprise Value 226023789 | Price to Sales(TTM) 2.5 | ||
Enterprise Value to Revenue 1.15 | Enterprise Value to EBITDA -133.96 | Shares Outstanding 127223778 | Shares Floating 108730530 |
Shares Outstanding 127223778 | Shares Floating 108730530 | ||
Percent Insiders 9.24 | Percent Institutions 63.33 |
Upturn AI SWOT
Cytek Biosciences Inc
Company Overview
History and Background
Cytek Biosciences Inc. was founded in 2014, emerging from the cytometry division of Amnis Corporation, which itself was acquired by EMD Millipore. Cytek pioneered Full Spectrum Profilingu2122 (FSPu2122) technology, revolutionizing cell analysis by enabling researchers to extract more information from biological samples.
Core Business Areas
- Cell Analysis Instruments: Cytek develops, manufactures, and commercializes cell analysis instruments that utilize its Full Spectrum Profiling (FSP) technology. These instruments include the Aurora and Northern Lights series, which are full spectrum flow cytometers.
- Reagents: Cytek provides a range of reagents, including antibodies, dyes, and kits, that are optimized for use with its cell analysis instruments. This includes cFluor reagents.
- Services: Cytek offers a variety of services, including instrument training, application support, and custom assay development, to assist customers in their research efforts.
Leadership and Structure
Cytek Biosciences is led by Wenbin Jiang, PhD., as CEO. The company has a typical corporate structure with departments covering R&D, manufacturing, sales, marketing, finance, and operations. The Board of Directors provides oversight and strategic direction.
Top Products and Market Share
Key Offerings
- Aurora Cell Analyzer: The Aurora Cell Analyzer is Cytek's flagship product, employing Full Spectrum Profiling (FSP) technology to provide high-resolution, high-content cell analysis. While precise market share data is not publicly available, Aurora is a leading competitor in the advanced flow cytometry market, especially for researchers needing high-parameter analysis. Competitors include BD Biosciences, Thermo Fisher Scientific, and Beckman Coulter.
- Northern Lights Cell Analyzer: The Northern Lights Cell Analyzer is a more accessible full spectrum cytometer, offering similar benefits to Aurora but at a lower price point and with a smaller footprint, targeting a broader range of research labs. It broadens Cyteku2019s footprint in the cell analysis market, competing with mid-range cytometers from BD Biosciences and Thermo Fisher Scientific. Cytek does not break out the revenue from this product.
- cFluor Reagents: A growing portfolio of reagents designed to enhance the benefits of Full Spectrum Profiling. A substantial source of recurring revenue, with Thermo Fisher Scientific and BioLegend being major competitors.
Market Dynamics
Industry Overview
The cell analysis market is driven by increasing research activity in areas such as immunology, cancer biology, and drug discovery. Technological advancements, particularly in multi-parameter flow cytometry and spectral flow cytometry, are fueling market growth. Demand is also increasing for research in single-cell technologies.
Positioning
Cytek is positioned as a leader in the high-end cell analysis market with its innovative Full Spectrum Profiling technology. Its competitive advantages include the ability to extract more information from biological samples, high sensitivity, and a user-friendly interface.
Total Addressable Market (TAM)
The total addressable market for flow cytometry and cell analysis is estimated to be in the billions of dollars, with continuous growth projected. Cytek is positioned to capture a significant share of this market through its innovative technology and expanding product portfolio. Estimates for the overall market are $5-7 Billion in 2024.
Upturn SWOT Analysis
Strengths
- Innovative Full Spectrum Profiling (FSP) technology
- High-resolution, high-content cell analysis
- Strong brand reputation in the research community
- Growing portfolio of reagents optimized for FSP
- Strong customer support and training programs
Weaknesses
- High price point may limit adoption in some markets
- Reliance on research market, which can be cyclical
- Relatively smaller sales and marketing organization compared to larger competitors
- Manufacturing capacity/supply chain dependencies
Opportunities
- Expansion into new applications, such as clinical diagnostics
- Geographic expansion, particularly in emerging markets
- Development of new reagents and consumables
- Partnerships with pharmaceutical and biotechnology companies
- Further technology innovation to solidify market leadership
Threats
- Competition from established players with larger market share
- Technological advancements from competitors
- Economic downturns impacting research funding
- Changes in regulatory environment
- Supply chain disruptions and inflationary pressures
Competitors and Market Share
Key Competitors
- BDX
- TMO
- BEC
Competitive Landscape
Cytek's advantage is its Full Spectrum Profiling (FSP) technology, which allows for greater resolution of cell populations than traditional flow cytometry. Its disadvantage is its smaller size and salesforce relative to larger competitors like BDX and TMO.
Major Acquisitions
ImpediBio
- Year: 2024
- Acquisition Price (USD millions): 51
- Strategic Rationale: Expands capabilities in label-free cell analysis, potentially revolutionizing cell characterization and sorting.
Growth Trajectory and Initiatives
Historical Growth: Cytek has experienced rapid revenue growth due to the adoption of its Full Spectrum Profiling technology. Growth has been driven by new instrument sales and increased reagent consumption.
Future Projections: Future growth is projected to continue, driven by increasing demand for high-content cell analysis, geographic expansion, and new product development. Analyst estimates vary depending on market conditions and competitor actions.
Recent Initiatives: Recent initiatives include expanding the reagent portfolio, launching new instrument configurations, increasing presence in emerging markets, and acquisition of other related businesses.
Summary
Cytek Biosciences is a strong company with innovative technology that is well-positioned in the cell analysis market. The Full Spectrum Profiling (FSP) technology is a key differentiator, and the company has a strong brand reputation. However, Cytek needs to be mindful of larger, more established competitors, economic downturns, and potential disruptions in research funding that could affect future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Investor Presentations
- Analyst Reports (where available)
- SEC Filings (10-K, 10-Q)
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is approximate and may vary depending on the source. Future performance is subject to various risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytek Biosciences Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2021-07-23 | President, CEO & Chairman of the Board Dr. Wenbin Jiang Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 688 | Website https://cytekbio.com |
Full time employees 688 | Website https://cytekbio.com | ||
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.